Long-term safety and effectiveness of velaglucerase alfa in Gaucher disease: 6-year interim analysis of a post-marketing surveillance in Japan

Table 3 IRRs reported for Japanese patients with GD

	Total	Severity	Action taken	Outcome
Patients with IRRs, n (%)	3 (10)
IRRs, n	5
Erythema	1	Moderate	Dose reduced	Resolved
Pyrexia	1	Mild	No change	Resolved
Swelling of eyelid	1	Mild	No change	Resolved
Tachycardia	1	Moderate	Dose reduced	Resolved
Vomiting	1	Moderate	Drug withdrawn	Resolved
Patients with serious IRRs, n (%)	1 (3)
Vomiting	1		Drug withdrawn	Resolved

All infusion-related reactions following treatment with velaglucerase alfa are presented, as well as data on the severity, action taken and outcome
IRR infusion-related reactions

ISSN: 1750-1172